A Novel Animal Model for Locally Advanced Breast Cancer

Annals of Surgical Oncology

Volumn 22, Issue 3, 2015, Pages 866-873

  Bogachek, Maria V ^a   Park, Jung Min ^a   De Andrade, James P ^a   Kulak, Mikhail V ^a   White, Jeffrey R ^a   Wu, Tong ^a   Spanheimer, Philip M ^a   Bair, Thomas B ^b   Olivier, Alicia K ^a   Weigel, Ronald J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PACLITAXEL; PROTEIN P53; SUMO PROTEIN; MESSENGER RNA; TUMOR MARKER;

ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NODULE; MOUSE; NONHUMAN; ONCOGENE; PLEURA EFFUSION; PLEURA METASTASIS; PNEUMONIA; PROTEIN EXPRESSION; RESPIRATORY FAILURE; SEPSIS; SHORT TANDEM REPEAT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; DISEASE MODEL; DNA MICROARRAY; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; NUDE MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925490070     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4174-8     Document Type: Article

References (33)

1. Simos D, Clemons M, Ginsburg OM, Jacobs C. Definition and consequences of locally advanced breast cancer. Curr Opin Support Palliat Care. 2014;8:33–38.
2. Tiezzi DG, de Andrade JM, Marana HR, Garieri AP, de Paula Philbert PM. Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer. Breast J. 2009;15:333–338.
3. Kai K, Arima N, Miyayama H, Yamamoto Y, Iwase H, Nishimura R. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin–docetaxel neoadjuvant chemotherapy: a cohort study. Breast Cancer. 2009;16:42–48.
4. Giordano SH. Update on locally advanced breast cancer. Oncologist. 2003;8:521–530.
5. Miglietta L, Vanella P, Canobbio L, et al. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology. 2010;79:255–261.
6. Bonnefoi H, Diebold-Berger S, Therasse P, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol. 2003;14:406–413.
7. Spanheimer PM, Carr JC, Thomas A, et al. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg. 2013;206:2–7.
8. O’Neill CF, Urs S, Cinelli C, et al. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol. 2007;171:1023–1036.
9. Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001;7:691–703.
10. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–5511.
11. Cyr AR, Kulak MV, Park JM, et al. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene. In press.
12. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods Cell Biol. 2008;86:311–324.
13. Pan Z, Hooley J, Smith DH, Young P, Roberts PE, Mather JP. Establishment of human ovarian serous carcinomas cell lines in serum free media. Methods. 2012;56:432–439.
14. Kao J, Salari K, Bocanegra M, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009;4:e6146.
15. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49–53.
16. Bogachek MV, Chen Y, Kulak MV, et al. Sumoylation pathway is required to maintain the Basal breast cancer subtype. Cancer Cell. 2014;25:748–761.
17. Fukuda I, Ito A, Hirai G, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol. 2009;16:133–140.
18. Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol. 2013;2013:219869.
19. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685.
20. Giacchetti S, Porcher R, Lehmann-Che J, et al. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer. 2014;110:1413–1419.
21. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:1821–1828.
22. Zhang H, Cohen AL, Krishnakumar S, et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 2014;16:R36.
23. Lin CH, Lien HC, Hu FC, et al. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang Univ Sci B. 2010;11:1–9.
24. Chebil G, Bendahl PO, Ferno M. Estrogen and progesterone receptor assay in paraffin-embedded breast cancer—reproducibility of assessment. Acta Oncol. 2003;42:43–47.
25. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–2795.
26. Eralp Y, Keskin S, Akisik E, et al. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2alpha expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Am J Clin Oncol. 2013;36:215–223.
27. Miyake T, Nakayama T, Naoi Y, et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 2012;103:913–920.
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–3988.
29. Iqbal J, Chong PY, Tan PH. Breast cancer stem cells: an update. J Clin Pathol. 2013;66:485–490.
30. Alamgeer M, Ganju V, Kumar B, et al. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res. 2014;16:R44.
31. Lee HE, Kim JH, Kim YJ, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011;104:1730–1738.
32. Lu H, Hu L, Yu L, et al. KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer. Oncogene. 2014;33:2909–2917.
33. Jiang WG, Davies G, Martin TA, et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med. 2006;17:583–590.